Description
Imatinib mesylate is listed in the oncology-focused API portfolio. The page is a technical overview only; clinical, regulatory and commercial status must be established from approved product documentation.
← Back to all products
Oncology API / Pharmaceutical technical profile
Imatinib mesylate
methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
Category: Oncology APICAS No.: 220127-57-1Formula: C30H35N7O4S
Swati Industries portfolio01 02 03
Chemical & technical profile
Product nameImatinib mesylate
CategoryOncology API
CAS No.220127-57-1
Molecular formulaC30H35N7O4S
Molecular weight589.7 g/mol
PubChem CID123596
Research & Development
Impurity identification and fate mapping; genotoxic-impurity risk assessment where relevant; robust assay/related-substances methods; solid-state characterization; stability and packaging studies.
Analytical testing
Identity by IR/LC-MS/NMR; assay and related substances by HPLC/UPLC; residual solvents by GC; water content; XRPD/DSC and particle-size testing where specification-relevant.
Verified chemical reference
methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
Open PubChem reference ↗Technical overview only; not a validated manufacturing process or a claim of company capability. Confirm chemical form, CAS No., grade and specifications from the approved specification and batch COA.